Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
ISO 28822:2018 — Medical devices — Needle-based injection systems — Requirements and test methods
Unified requirements and test methods for needle-based injection systems — The current state of the art
ISO 28822:2018 consolidates and updates the requirements from ISO 28820 and test methods from ISO 28821 into a single cohesive standard for needle-based injection systems. It represents the current state of the art, incorporating feedback from a decade of global regulatory experience with the earlier editions.
1. Integrated Requirements Framework — From Design to Market Release
ISO 28822:2018 unifies the previously separate requirements and test methods documents into a single standard, eliminating cross-referencing inconsistencies and providing a clear, linear compliance pathway from design specification to market release. The standard follows the structure recommended by ISO 13485 for medical device quality management systems, integrating design control, purchasing controls, production process validation, and post-market surveillance into a coherent framework. This integrated approach ensures that design inputs (derived from user needs and risk analysis) are directly traceable to design outputs (specifications, drawings, and bills of materials) and design verification test methods.
A significant update in this edition is the enhanced emphasis on use-related risk analysis. The standard requires manufacturers to document a comprehensive use-error analysis following ISO 14971 and IEC 62366 methodologies, covering the complete use cycle from device preparation through injection to disposal. For each identified use error with potential for serious harm (e.g., wrong dose, wrong injection site, reuse of single-use device), the manufacturer must demonstrate that residual risk has been reduced to an acceptable level through design measures, protective measures in the device itself, or information for safety. The standard explicitly requires that the use-related risk analysis be updated based on post-market surveillance data, including adverse event reports, complaint data, and published literature.
| Design Phase | ISO 28822 Requirements | Deliverable | Verification Method |
|---|---|---|---|
| User needs | Clinical workflow analysis, user population characterisation | User needs specification | Clinical literature review, field studies |
| Design input | Functional, performance, safety, and interface requirements | Design input specification | Traceability matrix |
| Risk management | Hazard identification, risk estimation, risk control | Risk management file (ISO 14971) | FMEA, FTA, risk control verification |
| Design output | Detailed drawings, material specs, assembly procedures | Device master record | Design review |
| Verification | Conformance to design input per Clause 6 test methods | Verification test reports | Clause 6 testing |
| Validation | Simulated-use and clinical validation studies | Validation reports | Human factors testing, clinical evaluation |
| Process validation | IQ, OQ, PQ for critical manufacturing processes | Validation protocols and reports | Statistical process control |
| Post-market | Complaint handling, vigilance reporting, CAPA | Post-market surveillance plan | Trend analysis, periodic safety updates |
A common finding during regulatory audits of needle-based injection device manufacturers is an inadequate traceability matrix between design inputs and verification tests. ISO 28822:2018 requires bi-directional traceability: every design input requirement must link to at least one verification test, and every test must trace back to its originating requirement. This is particularly important for requirements derived from the risk management process, which are frequently overlooked in verification planning.
2. Performance Requirements for Special Device Categories
ISO 28822 introduces several new requirements for specialised device categories that were not explicitly addressed in the earlier editions. For autoinjectors and emergency-use devices (such as epinephrine autoinjectors and naloxone delivery systems), the standard specifies additional requirements for: visual and audible feedback confirming complete dose delivery, needle insertion depth consistency, and system reliability after extended storage at temperature extremes (50 °C for 3 months, then -20 °C for 1 month, simulating car glove-compartment storage). The standard requires that the device deliver the correct dose after all temperature conditioning sequences.
For dual-chamber devices used for lyophilised drug reconstitution, ISO 28822 specifies requirements for: the mixing completeness (residual undissolved material ≤ 1 % of total solids), mixing time consistency (CV < 20 %), and drug concentration uniformity after reconstitution (measured by HPLC or equivalent analytical method). The standard also addresses wearable injectors — devices designed to be worn on the body for extended drug delivery (30 minutes to several hours) — requiring that the injection site seal integrity be maintained during normal body movement, that the device be splash-proof (IPX4 minimum), and that the occlusion alarm function be tested with a simulated occlusion at the cannula tip.
When developing a dual-chamber reconstitution device, pay particular attention to the by-pass channel geometry in the syringe barrel. The by-pass channel — through which the diluent flows from the front chamber to the rear chamber containing the lyophilised powder — must be designed such that all diluent is reliably transferred within the specified mixing stroke. Computational fluid dynamics (CFD) analysis during the design phase can identify channel geometries that eliminate trapped air pockets and ensure complete mixing on the first attempt.
| Device Category | Additional Requirements | Test Method Reference |
|---|---|---|
| Autoinjector, emergency use | Visual + audible dose completion feedback, needle depth consistency, extreme temperature storage | Annex A (temperature cycling), Clause 6.4 (auto-insertion) |
| Dual-chamber reconstitution | Mixing completeness (≤ 1 % residual), mixing time CV < 20 %, concentration uniformity | Annex B (reconstitution), HPLC assay |
| Wearable injector | IPX4 ingress protection, occlusion alarm, body movement seal integrity | IEC 60529, Clause 6.8 (occlusion test) |
| Retractable needle | Retraction force ≥ 5 N, lock-out after retraction, no re-exposure | Clause 6.9 (retraction test) |
| Paediatric/adjustable dose | Dose setting lock, 0.01 mL minimum increment, half-dose accuracy | Clause 6.2 (dose accuracy), user interface testing |
3. Material Selection and Biocompatibility — Updated Requirements
ISO 28822:2018 updates the biocompatibility requirements to align with the latest ISO 10993 series revisions. The standard now explicitly requires chemical characterisation of all patient-contacting materials per ISO 10993-18, including identification and quantification of extractable substances using GC-MS, HPLC-MS, and ICP-MS analytical techniques. For drug-contacting materials, the standard introduces the concept of “process-related leachables” — substances introduced during the manufacturing process (such as mould release agents, cleaning agent residues, and ethylene oxide sterilisation by-products) — which must be identified and assessed for toxicological risk per ISO 10993-17.
The standard also addresses the specific challenge of silicone oil lubricant migration. Silicone oil (polydimethylsiloxane) used on syringe barrel inner surfaces and stoppers can migrate into the drug formulation over time, potentially forming visible particles or affecting the stability of protein-based drug products. ISO 28822 requires that manufacturers establish a silicone oil specification covering viscosity grade, quantity per unit area, and distribution uniformity; that the silicone oil be tested for biocompatibility per ISO 10993; and that the drug product compatibility be demonstrated through stability studies with the final assembled device rather than individual components separately.
Tungsten residues from the glass syringe barrel forming process represent a well-documented incompatibility risk with certain protein-based biologics. Tungsten can accelerate protein aggregation and oxidation, potentially compromising drug safety and efficacy. ISO 28822 alerts manufacturers to this risk and recommends that glass barrel suppliers provide tungsten content data, and that the drug product manufacturer verify compatibility through stressed stability studies (40 °C / 75 % RH for up to 6 months).
Frequently Asked Questions
Q1: What are the key differences between ISO 28822:2018 and the earlier ISO 28820 + ISO 28821 combination?
- Unified single document — eliminates cross-referencing inconsistencies between the two earlier standards.
- Enhanced use-related risk analysis requirements aligned with IEC 62366.
- New requirements for autoinjectors, dual-chamber, and wearable injectors not present in the earlier editions.
- Updated biocompatibility and chemical characterisation requirements per ISO 10993-18.
- Integrated design control pathway traceable from user needs through post-market surveillance.
Q2: Does ISO 28822:2018 replace national standards such as ANSI/AAMI/ISO 11608 for pen injectors?
ISO 28822:2018 is the overarching standard for all needle-based injection systems. The ISO 11608 series (currently being revised) provides pen-injector-specific requirements and test methods and is referenced by ISO 28822. Manufacturers of pen injectors must comply with both ISO 28822 and ISO 11608.
Q3: How does the standard address combination products (device + drug)?
The standard acknowledges that needle-based injection systems often function as combination products where the device and the drug are interdependent. It requires manufacturers to consider the device-drug interface throughout the product lifecycle, including assembly compatibility, drug stability in the primary container, functional performance with the specific drug formulation, and usability testing with the complete combination product.
Q4: What are the packaging and shelf-life requirements?
The standard requires that the sterile barrier system comply with ISO 11607-1 and ISO 11607-2. The device must maintain its sterility and functional performance throughout the claimed shelf life. Shelf-life validation must include real-time aging (permanent reference) and accelerated aging (at 55 °C, following ASTM F1980). Functional testing must be performed at end of shelf life, including dose accuracy, glide force, needle sharpness, and sterility barrier integrity.
